Movapo

Երկիր: Նոր Զելանդիա

Լեզու: անգլերեն

Աղբյուրը: Medsafe (Medicines Safety Authority)

Ակտիվ բաղադրիչ:

Apomorphine hydrochloride hemihydrate 5 mg/mL

Հասանելի է:

CARSL Consulting

INN (Միջազգային անվանումը):

Apomorphine hydrochloride hemihydrate 5 mg/mL

Դոզան:

5 mg/mL

Դեղագործական ձեւ:

Solution for infusion

Կազմը:

Active: Apomorphine hydrochloride hemihydrate 5 mg/mL Excipient: Hydrochloric acid Nitrogen Sodium metabisulfite Water for injection

Միավորները փաթեթում:

Syringe, Prefilled 5 x 10mL, 5 dose units

Դաս:

Prescription

Ռեկվիզորի տեսակը:

Prescription

Պատրաստված է:

Macfarlan Smith Ltd

Թերապեւտիկ ցուցումներ:

Apomine PFS is indicated for the treatment of motor fluctuations ('on-off' phenomena) in patients with Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson's medication.

Ապրանքի ամփոփագիր:

Package - Contents - Shelf Life: Syringe, Prefilled 5 x 10mL - 5 dose units - 24 months from date of manufacture stored at or below 25°C protect from light

Հաստատման ամսաթիվը:

2006-08-03

Ապրանքի հատկությունները

Data Sheet – New Zealand

APOMINE
TM
 PFS 

NAME OF THE MEDICINE 
Apomorphine hydrochloride 

The CAS registry number of apomorphine hydrochloride, anhydrous is
41372-20-7 and the chemical 
structure is shown below: 

N
HO
Me
HO
H
.
HCl

DESCRIPTION 
Apomine
TM
 Pre-Filled Syringe (PFS) solution for subcutaneous (SC) infusion is
a clear, colourless 
and practically particle free sterile solution containing apomorphine
hydrochloride in Water for 
Injections BP.  Sodium metabisulfite 0.5 mg/ mL is included in the
formulation as an antioxidant.  
The pH of the injection is 3.0 to 4.0.   

Each 10 mL pre-filled syringe contains 50 mg apomorphine
hydrochloride, hence 1 mL of solution 
contains 5 mg apomorphine hydrochloride (5 mg/mL). 

PHARMACOLOGY 
Apomorphine is a directly acting dopamine receptor agonist,
structurally related to dopamine.  
Apomorphine has high _in vitro_ binding affinity for the dopamine D
4
 and D
5
 receptor (_K_
_i_
:4 and 14 nM 
respectively), moderate affinity (_K_
_i_
: 26 to 130 nM) for the dopamine D
2
 and D
3
, adrenergic 
α
1D
, 
α
2B
, 
α
2C
 receptors, serotonin 5HT
1A
, 5HT
2A
, 5HT
2B
 , and 5HT
2C
 receptors and low affinity for the 
dopamine D
1
 receptor (_K_
_i_
: 370 nM).  Apomorphine exhibits no affinity for the adrenergic ß
1
 and ß
2
 or 
histamine H
1
 receptors.   

The effect of apomorphine as an antiparkinsonian agent is believed to
be the result of direct 
stimulation of postsynaptic D
2
 dopamine receptors, but stimulation of presynaptic D
2
 dopamine 
receptors and antagonism of 
α
2
 adrenergic receptors may also be important.  Apomorphine reduces 
the tremor, rigidity and bradykinesia in patients receiving levodopa.
 Apomorphine induces vomiting 
by direct stimulation of the medullary chemoreceptor trigger zone. 

PHARMACOKINETICS 
The peripheral pharmacokinetics of apomorphine have
been studied following subcutaneous injection, 
subcutane